您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Panitumumab(anti-EGFR)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Panitumumab(anti-EGFR)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品名称
帕尼单抗 (anti-EGFR)
产品介绍
Panitumumab (anti-EGFR) 是一种全人源 IgG2 抗EGFR单克隆抗体，具有抗肿瘤活性。Panitumumab (anti-EGFR) 抑制肿瘤细胞增殖、存活和血管生成。Panitumumab (anti-EGFR) 可用于癌症研究，例如结肠癌。
生物活性

Panitumumab (anti-EGFR) is a fully humanIgG2anti-EGFRmonoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as coloncancer[1][2][4].

体外研究
(In Vitro)

Panitumumab (2 nM-2 μM, 3 h) (anti-EGFR) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) (anti-EGFR) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) (anti-EGFR) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].

Western Blot Analysis[3]

Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:2, 20, 200, 2000 nM
Incubation Time:3 h
Result:Inhibited ligand-induced autophosphorylation of EGFR.
体内研究
(In Vivo)

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P< 0.0003)[1].

Animal Model:NCI-H1975 and NCI-H1650 xenografts[3]
Dosage:25, 100, or 500 μg/mouse
Administration:Intraperitoneal injection (i.p.), twice a week
Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
Clinical Trial
性状

Liquid

中文名称

帕尼单抗 (anti-EGFR)

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.